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A
nalysis of the local immunological
microenvironment in colorectal
cancer lesions yielded prognostic markers.
Harnessing these insights for clinical
application however requires the use of
sophisticated technology and algorithms,
especially the robust and reproducible
quantification of immune cells. These
technologies are available and will
allow individualized treatment decisions
beyond the current standard.
The role of the immune system in the
course of cancer—and especially colorectal
cancer—has been debated for decades.
Recent data support a prognostic role of
the local tumor microenvironment to the
point, where an application in clinical
settings should be discussed. The technical
and immunological aspects that govern
such an endavour are discussed here and
show the development in this field.
Historically, the lack of appropriate
tools for analysis of immune cell infiltrates
precluded precise investigations in the
past. Therefore, the presence of immune
cells in cancer lesions was viewed as a
general inflammatory response promoting
cancer growth or a specific immune res-
ponse with respect to the immunosurveil-
lance theory or it was simply dismissed as
not relevant. In fact, pathologists typically
do not evaluate the immune cell presence,
but it were pathologists who also noted
the association between the presence of
large infiltrates and a better prognosis
in colorectal cancer patients.
1 With
more sophisticated methodology at hand,
analyses became more focused on the
immunological setup within the cancer
microenvironment and factors weighing
in on the interaction between immune
cells and cancer cells were better charac-
terized.
2-4 The use of immunohistochem-
istry to delineate the effects of different
immune cell populations and their spatial
distribution within and around cancer
lesions became more sophisticated and
generally identified T cells as a driving
force behind a better prognosis in colo-
rectal cancer patients.
5-9 The distinct
interplay between immune cell subpopula-
tions and their diverging roles allowed
a better differentiation: dendritic cells,
macrophages (with anti-tumor properties),
Th1 T cells and especially cytotoxic T cells
and natural killer cells are seen as protec-
tive factors for the host, while cancer-
associated macrophages (formerly termed
M2), myeloid-derived suppressor cells,
neutrophils, Th2 and Th17 T cells, and
FOXP3-positive regulatory T (Treg) cells
are seen as cancer-promoting.
10,11 The
precise function and effect on cancer cells
and other immune cells of the above
mentioned cells in different cancer entities,
their composition and the identification
of novel phenotypic subpopulations is
still ongoing and highlights the comple-
xity of the microenvironment.
Following the early observations more
sophisticated and systematic analyses on
large cohorts of patients were conducted.
12
These elegant studies then could convin-
cingly identify the prognostic role of T cell
infiltrates in the center and at the invasive
margin of the primary tumor.
13 Further
analysis of specific stages of colorectal
cancer brought more insight into the
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effects of different immune cell popula-
tions.
14-16 The role of regulatory T cells
within the colorectal cancer microenviron-
ment remains controversial. These cells
are mainly identified by FOXP3 expres-
sion and their presence is either attri-
buted to a favorable prognosis or a worse
prognosis. Further delineation of regula-
tory T cell and regulatory immune cell
subpopulations and better ways to identify
these will most likely yield clarifying
insights. This matter however highlights
a fundamental problem in the analysis
of cells on histology sections, especially
immune cells. Quantification of immune
cells with robust and reproducible results
is problematic for human observers. This
problem of quantification is long known
and leads to difficulties in reproducibility
and robustness. Human observers are
especially good at discerning extremes:
high densities vs. low densities. But gradi-
ents beyond “black and white” are very
problematic, an issue that is prominently
present in HER2/neu quantification. Even
for direct counting of low cell numbers,
the reproducibility for the same observer
is low.
17 It is impossible for a human
observer to reliably count cells in con-
glomerates and as such a semi-quantitative
estimation is the common solution.
However, all approaches with one ore
more human observers are extremely
time consuming and can only analyze
a minute fraction of the actual tumor
tissue. A solution to this is the use of
computational image analyses, where the
quantification is based directly on mor-
phological and spectral information of
detected cells.
18 Using thin sections, one
can ascertain that no overlapping cells
in conglomerates are present. Conglo-
merates are analyzed based on their area
and conformation and a statistical dataset
then allows the reproducible deduction
of the immune cells present within.
Robustness and reproducibility are how-
ever only one side of the benefits of
an automated quantification algorithm.
Coupling this methodology to whole
slide scanning, the question of immune
cell heterogeneity can be adressed system-
atically. Using an artifical grid as over-
lay, regions of 1 mm
2 area can be
quantified and the whole lattice then can
be visualized (Fig. 1). The observed
heterogeneity for primary colorectal cancer
showed enormous variability and in the
end leads to a technical question: can we
reliably measure the cell numbers based
on a single selected area of approximately
1m m
2? A typical core from a tissue
microarray has a surface area of 0.3 mm
2.
The answer for individual patients is: no,
the analyzed area has to be much larger
for robustness.
19 The average number of
CD3
+ T cells converges if more then five
fields of 1 mm
2 are analyzed for primary
colorectal cancer. So it is necessary to
analyse a tissue surface area large enough
to achieve reliability for a single patient.
This immune cell heterogeneity within
the tumor tissue is evident, even when
corrected for e.g., necrotic areas.
19 It is
important to see, that for each tumor
entity and for each marker analyzed (e.g.,
CD3, FOXP3, CD8, CD45RO, etc.), this
minimum surface tissue area has to be
calculated for robustness. Combining
whole slide imaging with a powerful
image analysis algorithm allows the robust-
ness and reproducibility needed for
personalized diagnostics. Coupling these
technologies to a dedicated tissue prepara-
tion workflow is going to deliver a basis
for treatment decisions (Fig. 2). Colorectal
cancer prognosis is influenced by the
presence of T cells in the stroma, within
the invasive front, and in the parenchyma,
in an intraepithelial localization. So what
is the best region for quantification: the
invasive margin or the center of the
tumor, or the stroma? Heterogeneity is
present in all regions and one of the
obvious aspects is the accumulation of
immune cells in distinct regions or com-
partments. The stroma, either peritumoral
or within the tumor lesion, harbors the
vast majority of immune cells, only small
percentages of T cells are in close contact
with the tumor epithelium.
20 In contrast,
macrophage populations are in direct
contact with a high percentage of infiltra-
ting T cells.
3 Furthermore, the presence
or absence of broad peritumoral stroma
does not automatically dictate the quan-
tity of immune cells present in the tumor
or around the tumor.
20
Colorectal cancer liver metastases have
not been analyzed often with a focus on
immunology.
21,22 For the medical onco-
logist a patient with advanced cancer and
liver metastases however is a daily chal-
lenge. While surgical approaches and
chemotherapy regimens have improved,
the prognosis for patients with irresectable
metastatic disease is still around 24 mo.
The tantalizing data from the large
Figure1. Workflow example for the generation of a whole slide “immunomap”, visualizing the
immune cell density and heterogeneity across the tissue section. (A) Overview of the tissue section
(B) Different regions of interest for analysis (C) Grid construction on the tumor lesion (grid size is
typcially 1 mm
2 per tile) (D) Coloring of grid tiles according to immune cell quantities revealing the
heterogeneity.
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systematic analyses showed that there are
indeed at least two immunological patient
subgroups for each UICC stage: patients
with a high infiltrate density and patients
with a low infiltrate density. The latter
fare much worse and their prognosis is
sometimes even worse then the prognosis
for patients with a more advanced UICC
stage. So the next question was: how is the
local immune infiltration in colorectal
cancer liver metastases and is it related
to the clinical outcome? One surprising
observation was that one could not predict
the infiltrate density at the liver metastasis
from looking at the primary tumor.
20
While sometimes there was concordance
in the infiltrate density between primary
tumor and metastasis, more often there
was discordance. Furthermore it was
remarkable that there is a clear border
at the invasive margin of liver metastases,
showing a strong variability in T cell
densities between samples from different
patients. The T cell infiltrate at the inva-
sive margin of the liver lesion also did not
correspond to the infiltrate density within
the metastasis. So all combinations were
observed: strong infiltrate at the invasive
margin and almost no infiltration within
the metastasis, less infiltrate at the inva-
sive margin but strong infiltration of the
metastatic lesion, almost no infiltrate at
the invasive margin and almost no infilt-
rate within the metastasis and so on. In
metastatic lesions, the microenvironment
of the inner tissue is more often governed
by necrosis and cell debris, making it
difficult to compare these inner regions
between different patients. Surprisingly,
the invasive margin was found to be
informative for prognosis of these patients
and is informative in the prediction of
chemotherapy response. In a selected
cohort of patients, from which samples
with the invasive margin of liver metasta-
ses could be analyzed, the score based
on the infiltrate density of CD3, CD8
or Granzyme B positive immune cells
allowed to predict treatment response
in these patients.
23 While in previous
studies, only the completely resected
primary tumor was analyzed and there-
fore the “escaped” tumor cells could not
be analyzed,
24 the patients for this new
analysis either had a diagnostic excision
(during resection of the primary tumor or
laparoscopy) or in a few cases had a biopsy
containing a large stretch of the invasive
margin of the liver lesion. So the analysis
of the tissue is the analysis of the actual
tissue that is then treated with (first line)
chemotherapy, allowing for the first time
to analyze large stretches of invasive
margin and correlate this with the clinical
course. In essence, the TIL densities at
the invasive margin of liver metastases
allowed the prediction of response to
chemotherapy with a sensitivity of 79%
and specificity of 100%. The association
of high density values with longer pro-
gression free survival under chemotherapy
was also statistically significant. This raises
of course several important questions:
what is the effect of these cells during or
after chemotherapy? Two hypotheses can
be proposed: either chemotherapy leads
to immunomodulation, i.e., suppression
of inhibitory immune cell function, allow-
ing the peritumoral T cells to infiltrate
and attack cancer cells. This is a hypo-
thesis that is in line with the cancer
immunosurveillance theory developed by
R. Schreiber and coworkers.
25 Or, as
an alternative or additional explanation,
Figure2. Individualized analysis of the immune cell profiles for the stratification of patients.
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chemotherapy induces an immunogenic
cell death that leads to renewed activation
of the effector immune cells, the recog-
nition of novel epitopes or a general
unspecific activation of the immune
system and thereby provides new targets
to immune cells.
10,26,27
Overall, these findings extend the
impact of the local immune response
on the clinical course from the primary
tumor also to metastatic lesions. While
untreated reference samples cannot be
expected to be available in larger numbers
due to ethical reasons, efforts to compile
a set of these rare specimens are ongo-
ing. This then can clarify whether the
immune infiltrate density is prognostic
and predictive in the strictest sense. It
also remains to be seen whether this
observation from large stretches of inva-
sive margin can be transferred to unselec-
ted biopsies from patients with liver
metastases from colorectal cancer. The
clinical need is there and an improve-
ment beyond the almost 50% chemother-
apy failure rate is desireable. A trial will
adress this question soon. But also another
question rises from these observations:
what dictates the presence of these lym-
phocytes within the tissue and especially
at the invasive margin? And can this be
exploited? From the primary tumor we
have ample data that identifies the cyto-
kines and chemokines involved in this
process.
28-30 Key factors are CXCL10
and CXCL9, which may attract (memory)
T cells as well as CX3CL1 (also known
as fractalkine), which may attract Th1
cells to the tumor site. It is surprsing
to see, that these cytokine regulation is
weakened in colorectal cancer liver meta-
stases and even more surprising to see
that natural killer cells are generally scarce
in colorecal cancer, despite the presence
of activating and recruiting cytokines
and chemokines.
30 The analysis of the
metastatic situation is ongoing and new
therapeutic options are of pressing need
for the clinician. From a clinical perspect-
ive, the measurement of a distinct pro-
tein in the peripheral blood that reflects
the immunologic situation within the
tumor lesion is highly desireable. So
far, there has been no good candidate
for this application and the major source
for relevant parameters for patient strati-
fication is the analysis of the local tumor
bed.
In the future, treatment decisions based
on immune cell profiling require auto-
mated and robust approaches to open
the door for personalized medicine in
oncology. Multiplex immunohistochem-
istry on single slides will allow the efficient
analysis of samples and speed up the
process of quantification. High detail
levels in the analysis of immune cells
and their cytokines and chemokines are
broadening the understanding of the
processes in the microenvironment. The
interplay between immune cells, antigeni-
city of the tumor cells and immunosup-
pressive mechanisms at the local site has
the potential to open new therapeutic
avenues. Especially in the light of spatial
relations and quantitative biology there
is plenty of translational research that can
be performed.
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